Kichloo, A., Albosta, M., Kumar, A., Aljadah, M., et al. (2021) Emerging Therapeutics in the Management of COVID-19. World Journal of Virology, 10, 1-29.
https://doi.org/10.5501/wjv.v10.i1.1

has been cited by the following article:

• TITLE: Persistence of Anti-SARS-CoV-2 IgM Antibody up to 8 Months Post-COVID-19

  AUTHORS: Carlos David A. Bichara, Ednelza S. G. Amoras, Gergiane L. Vaz, Cléa N. C. Bichara, Isabella P. C. Amaral Amaral, Antonio C. R. Vallinoto

  KEYWORDS: COVID-19, SARS-CoV-2, Antibodies, IgM, Persistence

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.10 No.9, August 31, 2021

  ABSTRACT: Here, we present a longitudinal analysis of two patients who recovered from COVID-19 more than 8 months prior but showed persistent serological detection of anti-SARS-CoV-2 IgM. We still do not know the exact reason for this prolonged persistence of IgM in these patients. To our knowledge, these are the first reports of IgM persistence in the context of SARS-CoV-2 infection and point to the need for no longer using IgM as a diagnostic criterion for acute or recent COVID-19. One should opt for gold standard molecular methodologies due to their high sensitivity and specificity.